Last edition
News about "Dr Dongxu Shu"
Argo Biopharma to Present Phase II Interim Data on BW-20805 for HAE at AAAAI 2026
Argo Biopharma’s investigational siRNA therapy BW-20805 showed sustained reduction in hereditary angioedema attack rates and plasma prekallikrein levels, with favorable safety, in Phase II interim data selected for AAAAI 2026.
Dr Dongxu Shu | 27/02/2026 | By News Bureau
Argo Biopharma and Novartis Partner on Novel Cardiovascular Therapies
Argo to receive $160 million upfront as Novartis licenses pipeline assets, explores ANGPTL3 in dyslipidemia, and secures options for future siRNA candidates.
Dr Dongxu Shu | 05/09/2025 | By Dineshwori | 282
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy